A recent study suggested that the CDK4/6 inhibitor ribociclib could be used as an alternative to the MEK inhibitor trametinib to improve the efficacy of the SHP2 inhibitor TNO155 in KRAS-mutant CRC and showed better tolerability. Here, KRAS is linked to colorectal carcinoma.